Comparison
WAY-316606 vs Minoxidil
Wnt agonist vs. classic K-ATP opener: niche stack-extender versus proven regrowth staple.
WAY-316606
SFRP1 Antagonist (Wnt Activator)
Minoxidil
K-ATP Channel Opener / Vasodilator
Effectiveness Profile
At a Glance
| WAY-316606 | Minoxidil | |
|---|---|---|
| Type | Hair | Hair |
| Legal status | Research | OTC |
| Half-life | Not characterized in humans | 3.5–4 hours (oral) |
| Preferred route | Topical | Topical + Oral (stacked) |
| Dose frequency | once-daily | once-daily |
| Beginner dose | 2.5–5 mg | 1.25–2.5 mg |
| Intermediate dose | 5–10 mg | 2.5–2.5 mg |
| Advanced dose | 10–15 mg | 2.5–5 mg |
| Cycle length | 24–52 wks | 52–520 wks |
| Bioavailability | — | 90% |
| Time to peak | — | 1h |
| Active duration | — | 24h |
| Storage | Powder: -20°C, desiccated, protected from light. Reconstituted topical: 2–8°C refrigerated, amber bottle. | Room temperature, dry, away from light |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
WAY-316606 wins for: addressing the Wnt/β-catenin pathway directly (no overlap with DHT or AR signaling), introducing a novel mechanistic lever for stack plateau-busters, minimal systemic side effects (when topically administered), and high value as an add-on when the classic stack stalls.
Minoxidil wins for: sheer regrowth reliability, robust evidence base, off-the-shelf sourcing (topical and LDOM options), and ease of slotting into nearly any protocol as the anchor growth-promoter—especially for first-line or monotherapy use. Time to peak effect and overall magnitude still favor minoxidil for most responders.
Pick A or B?
Pick WAY-316606 if:
- The stack already includes minoxidil, a 5-AR inhibitor (finasteride/dutasteride), and possibly a topical AR antagonist, but growth has plateaued
- Avoiding hormone modulation (for AAS users, or anyone concerned with PFS or systemic 5-AR suppression)
- Desire a Wnt-pathway driver to maximize follicle anagen duration and shaft caliber
- Minoxidil is poorly tolerated (irritation, shedding, or non-response) and alternatives are needed
- Experimental research on novel targets is the core interest, especially for difficult or resistant cases
Pick Minoxidil if:
- Documented consistent regrowth is the primary priority
- Starting a stack from scratch and want the most evidence-backed anchor available
- Ease of sourcing and straightforward daily application is a must
- Need systemic (LDOM) or topical options with well-studied safety/tolerability
- Willing to commit to long-term, indefinite use (given the regression after discontinuation)